General Information of Drug (ID: DMQ6ANE)

Drug Name
TGOF02N Drug Info
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMQ6ANE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting 5-HT 2 receptor (5HT2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mianserin DMVKA4O Depression 6A70-6A7Z Approved [3]
Cyclobenzaprine DM1YBRM Depression 6A70-6A7Z Approved [4]
Perospirone DMVHJLX Psychotic disorder 6A20-6A25 Approved [5]
Ketanserin DMVLMW6 Hypertension BA00-BA04 Approved [6]
Bis(olanzapine) pamoate monohydrate DME76AP Psychotic disorder 6A20-6A25 Phase 3 [7]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [8]
Nexopamil DML5S71 Hypertension BA00-BA04 Phase 2 [9]
TGWOOAA DMI57ZA Generalized anxiety disorder 6B00 Phase 2 [10]
AMAP-102 DM7CD8Z Arthritis FA20 Phase 1 [11]
Heterocyclic-tetracyclic tetrahydrofuran derivative 1 DMNJVR6 N. A. N. A. Patented [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2 receptor (5HT2R) TTYSN63 NOUNIPROTAC Modulator [2]

References

1 Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
2 Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
3 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
4 Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
5 Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
6 Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
10 Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
11 Clinical pipeline report, company report or official report of Anamar.
12 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.